RIGL Earnings Results and History
Rigel Pharmaceuticals Inc's earnings at a glance: the latest results and outlook from the press release, revenue, margins and EPS for every quarter from the company's SEC filings, and how the stock moved after each report. New results show here within about a minute of being filed.
- EPS$0.65 vs $0.92 est −29.4%
- Revenue$80.9M vs $80.1M est +1.0%
- Revenue growth+16.5% vs a year ago
- Outlook Raised2026: $290M to $295M revenue
Filed ยท Press release
Key takeaways
from the press release- Total revenue rose 16% to $80.9 million, with net product sales up 13% to $72.3 million from the same quarter last year.
- VEPPANU launched in mid August and contributed $6.6 million in initial net product sales in its first weeks on the market.
EPS by quarter
GAAP diluted, 12 quartersRevenue and operating margin
from 10-Q and 10-KQuarter by quarter
from 10-Q and 10-K filings| Quarter ended | Revenue | Growth | Gross margin | Op margin | Net income | EPS |
|---|---|---|---|---|---|---|
| Jun 2026 | $78.7M | −22.6% | 89.2% | 30.0% | $17.3M | $0.88 |
| Mar 2026 | $58.8M | +10.3% | 92.2% | 20.2% | $8.7M | $0.44 |
| Dec 2025 | $69.8M | +21.2% | 91.5% | 33.2% | $268.1M | $14.10 |
| Sep 2025 | $69.5M | +25.6% | 93.2% | 40.9% | $27.9M | $1.46 |
EPS here is GAAP diluted, as filed with the SEC. Estimates are usually based on adjusted EPS, so the two can differ. Growth compares with the same quarter a year earlier.
Year by year
fiscal years, from 10-K filings| Year ended | Revenue | Growth | Op margin | Net income | EPS |
|---|---|---|---|---|---|
| Dec 31, 2025 | $294.3M | +64.1% | 42.6% | $367M | $19.48 |
| Dec 31, 2024 | $179.3M | +53.4% | 13.5% | $17.5M | $0.99 |
| Dec 31, 2023 | $116.9M | −2.8% | −17.5% | −$25.1M | −$1.44 |
| Dec 31, 2022 | $120.2M | −19.4% | −46.2% | −$58.6M | −$3.44 |
| Dec 31, 2021 | $149.2M | – | −8.4% | −$17.9M | −$0.11 |
Filings and dates
SEC EDGAR- Nov 5, 2026Earnings release, Q3 20268-K Press release
- Nov 5, 2026Next earnings reportexpected
- Aug 4, 2026Quarterly report10-Q All filings
Also see RIGL institutional ownership and the earnings calendar.
RIGL earnings FAQ
What were RIGL's latest earnings?
For Q3 2026 Rigel Pharmaceuticals Inc reported revenue of $80.9M, GAAP EPS of $0.65. The results were filed with the SEC on Nov 5, 2026.
When is RIGL's next earnings date?
Rigel Pharmaceuticals Inc is expected to report on Nov 5, 2026. Dates can move until the company confirms them.
Is RIGL's revenue growing?
In the quarter ended Jun 30, 2026 revenue was $78.7M, down 22.6% from a year earlier. The table on this page shows every quarter from the company's 10-Q and 10-K filings.
Where do these numbers come from?
Results, guidance and financials come from Rigel Pharmaceuticals Inc's own SEC filings: the earnings press release (Form 8-K) and the quarterly and annual reports (10-Q and 10-K). Key takeaways summarize the press release. Estimates and price moves come from market data.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Results come from company filings with the SEC. Estimates are consensus figures from before each report. Key takeaways summarize the company's press release and may contain errors; the press release is the authoritative source.